Researchers at University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis
When you use our products, you can be confident that your timeline is being dictated by biology, not by poor manufacturing
Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, et al
Karen Mann, MD, Nooms Medical Director , for her insights